内視鏡的粘膜下層剥離術（EIS）市場は、2025年の5億ドルから2030年には7億5,000万ドルに達し、予測期間中は年平均成長率（CAGR）8.4%で成長すると予想されます。内視鏡的粘膜下層剥離術市場の主要プレーヤーには、オリンパス株式会社 (日本)、富士フイルムホールディングス株式会社 (日本)、メドトロニック(アイルランド)、ボストンサイエンティフィックコーポレーション(米国)、住友ベークライト株式会社(日本)、クレオメディカルグループPlc(英国)、HOYA株式会社 (日本)、ConMedコーポレーション(米国)、STERIS(アイルランド)、MTW Endoskopie Manufaktur(ドイツ)、Ovesco Endoscopy AG(ドイツ)、ゼオンメディカル株式会社 (日本)、Micro-Tech Endoscopy(中国)、 Karl Storz SE & Co. KG(ドイツ)、Cook Medical(米国)など。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 INCLUSIONS AND EXCLUSIONS
1.4 YEARS CONSIDERED
1.5 CURRENCY USED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET OVERVIEW
4.2 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT AND COUNTRY
4.3 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: GEOGRAPHIC MIX
4.4 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION
4.5 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DEVELOPED VS. DEVELOPING MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of endoscopy in detection and treatment procedures
5.2.1.2 Rising prevalence of cancer
5.2.1.3 Growing geriatric population
5.2.2 RESTRAINTS
5.2.2.1 Dearth of skilled professionals
5.2.2.2 High overhead cost of ESD procedures with limited reimbursements
5.2.3 OPPORTUNITIES
5.2.3.1 Growing demand for minimally invasive procedures
5.2.3.2 Expected increase in adoption of and preference for ESD procedures in developing countries
5.2.4 CHALLENGES
5.2.4.1 Higher rate of complications
5.2.4.2 Risk of post-operative infection
5.3 INDUSTRY TRENDS
5.3.1 ADVANCES IN TRACTION METHODS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION
5.3.2 ROBOT-ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION
5.4 REGULATORY ANALYSIS
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4.2 REGULATORY LANDSCAPE
5.4.2.1 North America
5.4.2.1.1 US
5.4.2.1.2 Canada
5.4.2.2 Europe
5.4.2.2.1 Germany
5.4.2.2.2 France
5.4.2.2.3 UK
5.4.2.2.4 Italy
5.5 MARKET ECOSYSTEM
5.6 VALUE CHAIN ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.1.1 High capital requirement
5.7.1.2 High preference for products from well-established brands
5.7.2 THREAT OF SUBSTITUTES
5.7.2.1 Presence of substitute therapies for endoscopic submucosal dissection
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.3.1 Presence of several raw material suppliers
5.7.3.2 Supplier switching cost
5.7.4 BARGAINING POWER OF BUYERS
5.7.4.1 Limited number of companies offering premium products at global level
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.7.5.1 Increasing demand for high-quality and innovative products
5.7.5.2 Lucrative growth potential in emerging markets
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2024
5.8.2 AVERAGE SELLING PRICE TREND OF KNIVES, BY REGION, 2022-2024 (USD)
5.9 PATENT ANALYSIS
5.10 SUPPLY CHAIN ANALYSIS
5.11 KEY CONFERENCES AND EVENTS DURING 2025-2025
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 TRENDS/DISRUPTIONS AFFECTING CUSTOMER BUSINESS
5.13.1 TRENDS/DISRUPTION IMPACTING CUSTOMER'S BUSINESS
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA
5.14.2 EXPORT DATA
5.15 TECHNOLOGY ANALYSIS
5.15.1 KEY TECHNOLOGIES
5.15.1.1 Endoscopic electrosurgical knives
5.15.1.2 High-definition endoscopes
5.15.2 COMPLEMENTARY TECHNOLOGIES
5.15.2.1 Narrow band imaging/i-scan/FICE
5.15.2.2 Optical coherence tomography (OCT)
5.15.3 ADJACENT TECHNOLOGIES
5.15.3.1 Endoscopic mucosal resection
5.15.3.2 Full-thickness resection devices
5.16 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: ADJACENT MARKET
5.17 CASE STUDY ANALYSIS
5.17.1 ROBOTIC-ASSISTED ESD FOR ESOPHAGEAL TUMORS
5.17.2 COST-EFFECTIVE ESD DEVICES FOR STOMACH CANCER
5.17.3 PRECISION ESD FOR COLORECTAL CANCER LESIONS
5.18 IMPACT OF AI/GEN AI ON ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
5.18.1 MARKET POTENTIAL OF AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
5.18.2 AI USE CASES
5.18.3 KEY COMPANIES IMPLEMENTING AI
5.18.4 FUTURE OF GENERATIVE AI IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
5.19 IMPACT OF 2025 US TARIFF ON ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
5.19.1 KEY TARIFF RATES
5.19.2 PRICE IMPACT ANALYSIS
5.19.3 IMPACT ON END-USE INDUSTRIES
5.20 INVESTMENT & FUNDING SCENARIO
6 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 GASTROSCOPES & COLONOSCOPES
6.2.1 RISE IN COLON CANCER INCIDENCE TO DRIVE GROWTH
6.3 KNIVES
6.3.1 IMPROVED EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF KNIVES TO DRIVE MARKET GROWTH
6.4 INJECTION AGENTS
6.4.1 NEED FOR LOW-COST INJECTION AGENTS TO BOOST GROWTH
6.5 TISSUE RETRACTORS
6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO AID ADOPTION
6.6 GRASPERS/CLIPS
6.6.1 PATIENT SAFETY AND HIGH PRECISION OFFERED BY GRASPERS TO DRIVE DEMAND
6.7 OTHER PRODUCTS
7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION
7.1 INTRODUCTION
7.2 STOMACH CANCER
7.2.1 SIGNIFICANT PROPORTION OF CANCER DEATHS TO DRIVE SEGMENT
7.3 COLON CANCER
7.3.1 INTEREST BY MEDICAL DEVICE MANUFACTURERS, CLINICAL INVESTIGATORS, AND PRACTICING CLINICIANS TO DRIVE MARKET
7.4 ESOPHAGEAL CANCER
7.4.1 GROWING PREVALENCE OF ESOPHAGEAL CANCER TO FUEL GROWTH
8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES AND ESD PROCEDURES TO SUPPORT GROWTH
8.3 SPECIALTY CLINICS
8.3.1 TRANSITION FROM HOSPITAL-BASED PROCEDURES TO CLINIC-BASED PROCEDURES TO BOOST GROWTH
8.4 AMBULATORY SURGICAL CENTERS
8.4.1 GROWTH IN SEGMENT DRIVEN BY INCREASING NUMBER OF OUTPATIENT VISITS
8.5 OTHER END USERS
9 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION
9.1 INTRODUCTION
9.2 ASIA PACIFIC
9.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.2.2 JAPAN
9.2.2.1 Supportive medical device reimbursement policies to drive market growth
9.2.3 CHINA
9.2.3.1 Large patient population and strong need for healthcare infrastructure improvements to boost market growth
9.2.4 INDIA
9.2.4.1 Favorable government initiatives for healthcare infrastructure improvements to support market growth
9.2.5 SOUTH KOREA
9.2.5.1 Rapidly aging population and high incidence of gastrointestinal diseases to aid market growth
9.2.6 AUSTRALIA
9.2.6.1 High incidence of cancer to propel market growth
9.2.7 REST OF ASIA PACIFIC
9.3 NORTH AMERICA
9.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.3.2 US
9.3.2.1 Largest market for endoscopic submucosal dissection products
9.3.3 CANADA
9.3.3.1 Slower healthcare development over past decade to restrain growth
9.4 EUROPE
9.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.4.2 GERMANY
9.4.2.1 Germany to account for largest share of European market
9.4.3 FRANCE
9.4.3.1 High-quality healthcare system offering coverage to all citizens to support market growth
9.4.4 UK
9.4.4.1 Investments by hospitals to purchase new and advanced endoscopic submucosal dissection equipment to propel market
9.4.5 ITALY
9.4.5.1 Receptivity of government toward high-quality and technologically advanced equipment to foster growth
9.4.6 SPAIN
9.4.6.1 Rising prevalence of cancer to drive market growth
9.4.7 REST OF EUROPE
9.5 LATIN AMERICA
9.5.1 INCREASING PURCHASING POWER AND HEALTHCARE AFFORDABILITY TO FAVOR MARKET GROWTH
9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.3 BRAZIL
9.5.3.1 Increase in private healthcare investments and rise in medical tourism to aid market growth
9.5.4 MEXICO
9.5.4.1 Increased government investment in healthcare infrastructure and technological advancements to aid market growth
9.5.5 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 ADVANCEMENTS IN HEALTHCARE INFRASTRUCTURE TO CREATE NEED FOR HOSPITAL EQUIPMENT AND MEDICAL DEVICES
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.7 GCC COUNTRIES
9.7.1 INCREASING INVESTMENT IN HEALTHCARE INFRASTRUCTURE AND GROWING MEDICAL TOURISM TO PROPEL MARKET GROWTH
9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
10.3 REVENUE ANALYSIS
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product footprint
10.5.5.4 Indication footprint
10.5.5.5 End user footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of key startups/SMEs
10.7 COMPANY VALUATION AND FINANCIAL METRICS
10.7.1 FINANCIAL METRICS
10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 OLYMPUS CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Deals
11.1.1.3.2 Expansions
11.1.1.4 MnM view
11.1.1.4.1 Right to win
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 MEDTRONIC
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 MnM view
11.1.2.3.1 Right to win
11.1.2.3.2 Strategic choices
11.1.2.3.3 Weaknesses and competitive threats
11.1.3 FUJIFILM HOLDINGS CORPORATION
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Product launches & approvals
11.1.3.3.2 Deals
11.1.3.4 MnM view
11.1.3.4.1 Right to win
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 BOSTON SCIENTIFIC CORPORATION
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 MnM view
11.1.4.3.1 Right to win
11.1.4.3.2 Strategic choices
11.1.4.3.3 Weaknesses and competitive threats
11.1.5 SUMITOMO BAKELITE CO., LTD.
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 MnM view
11.1.5.3.1 Right to win
11.1.5.3.2 Strategic choices
11.1.5.3.3 Weaknesses and competitive threats
11.1.6 CREO MEDICAL GROUP PLC
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 HOYA CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.8 CONMED CORPORATION
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.9 STERIS
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Deals
11.1.10 MTW ENDOSKOPIE MANUFAKTUR
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.11 OVESCO ENDOSCOPY AG
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.12 ZEON MEDICAL INC.
11.1.12.1 Business overview
11.1.12.2 Products offered
11.1.13 MICRO-TECH ENDOSCOPY
11.1.13.1 Business overview
11.1.13.2 Products offered
11.1.13.3 Recent developments
11.1.13.3.1 Product launches
11.1.14 KARL STORZ SE & CO. KG
11.1.14.1 Business overview
11.1.14.2 Products offered
11.1.15 COOK MEDICAL
11.1.15.1 Business overview
11.1.15.2 Products offered
11.1.15.3 Recent developments
11.1.15.3.1 Product launches
11.2 OTHER COMPANIES
11.2.1 LEO MEDICAL CO., LTD.
11.2.2 ERBE ELEKTROMEDIZIN GMBH
11.2.3 TAEWOONG MEDICAL CO., LTD.
11.2.4 DCC HEALTHCARE
11.2.5 KOSSEN CO., LTD.
11.2.6 INNOVAMEDICA S.P.A.
11.2.7 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
11.2.8 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.
11.2.9 BEIJING ZKSK TECHNOLOGY CO., LTD.
11.2.10 UPEX-MED CO., LTD.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
